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The illicit drug trade, dominated by sophisticated trans-national criminal 
organisations, has put increasing demands on law enforcement bodies. Timely 
information concerning illegal activity is required to effectively combat the illicit drug 
problem. Rapid, if not real-time, identification tools would help direct investigators 
with sampling procedures and safety precaution measures at drug-related crime 
scenes. In addition to enhancing work-flow processes, for example the creation of 
rapid laboratories or intelligence units, a major focus rests on the miniaturisation of 
existing analytical techniques, predominantly spectroscopic-based, in order to create 
field portable tools for this purpose. Currently available techniques such as colour 
tests, Raman and infra-red spectrometers often have limitations associated with 
specificity, portability and sample preparation requirements.  The diverse nature of 
exhibits present challenges for the in-field detection of controlled drugs and pre-
cursors. 
An emerging area of research, lab-on-a-chip (LOC), with its ability to integrate 
multiple functions on a microchip, has shown promising applications for in-field 
testing. The aim of this project was to evaluate a commercial portable microchip 
capillary electrophoresis (MCE) platform, the Agilent Bioanalyzer 2100, for the 
analysis of amphetamine-type stimulants (ATS). This device, although designed for 
the analysis of biological molecules, holds significant potential for the analysis of 
inorganic ions, explosives and illicit drugs. This project focused on developing and 
optimising a rapid, simple and inexpensive separation method. The method was 
adapted for the analysis of a wide range of casework exhibits including liquids, tablets 
and powders in order to test its in-field capabilities. The prospects, challenges and 
applications are discussed. This research has highlighted MCE as a competitive 
platform for the screening of ATS and has demonstrated its potential use in forensic 
drug analysis. 
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